Search
Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnAs well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.
Cyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.
Bevifimod
go.drugbank.com/drugs/DB15301InvestigationalBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
Peanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawn[A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547] The drug [MRTX849] is also currently being developed and has the same target.
Categories: RAS GTPase InhibitorsDienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalDienogest is commonly marketed as Visanne, Natazia and Qlaira. … It is a derivative of 19-nortestosterone and has antiandrogenic properties.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalIt was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Povidone-iodine
go.drugbank.com/drugs/DB06812ApprovedInvestigationalPovidone-iodine was immediately marketed, and has since become the universally preferred iodine antiseptic. … During in vitro testing to demonstrate anti-bacterial activity it was found that the complex was less toxic in mice than tincture of iodine.
Mixtures: Mas Care-pak DexamethasoneEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Synonyms: Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)